We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · September 23, 2019

BRAF/MEK Inhibition + PD-1 Blockade Immunotherapy Prolongs Response in BRAF-Mutant Melanoma

Nature Medicine

 

Additional Info

Nature Medicine
Combined BRAF and MEK Inhibition With PD-1 Blockade Immunotherapy in BRAF-Mutant Melanoma
Nat. Med. 2019 Jun 01;25(6)936-940, A Ribas, D Lawrence, V Atkinson, S Agarwal, WH Miller, MS Carlino, R Fisher, GV Long, FS Hodi, J Tsoi, CS Grasso, B Mookerjee, Q Zhao, R Ghori, BH Moreno, N Ibrahim, O Hamid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading